Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
First Claim
Patent Images
1. A modified cytokine that exhibits increased resistance to proteolysis compared to the unmodified cytokine or a modified cytokine selected from the group consisting of modified cytokines comprising a sequence of amino acids set forth in any of SEQ ID Nos. 2-181, 233-1303 or a structural homolog thereof.
5 Assignments
0 Petitions
Accused Products
Abstract
Processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided is a rational method for generating protein variants and the resulting variants.
-
Citations
331 Claims
-
1. A modified cytokine that exhibits increased resistance to proteolysis compared to the unmodified cytokine or a modified cytokine selected from the group consisting of modified cytokines comprising a sequence of amino acids set forth in any of SEQ ID Nos. 2-181, 233-1303 or a structural homolog thereof.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 279, 280, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331)
-
2. The modified cytokine of claim 1, selected from the group consisting of a member of the interferons/interleukin-10 protein family, a member of the long-chain cytokine family and a member of the short-chain cytokine family, wherein the modified cytokine is a modified interferon α
- of any of SEQ ID Nos. 87, 89, 90, 93, 96, 101, 103, 107, 124, 979, 980, 983, 984, 985, 986 and 987 or a cytokine modified on the basis of 3-dimensional structural homology with any of SEQ ID Nos. 87, 89, 90, 93, 96, 101, 103, 107, 124, 979, 980, 983, 984, 985, 986 and 987.
-
3. The modified cytokine of claim 1 selected from the group consisting of interleukin-10 (IL-10), interferon beta (IFNβ
- ), interferon alpha-2a (IFNα
-2a), interferon alpha-2b (IFNα
-2b), and interferon gamma (IFN-y), granulocyte colony stimulating factor (G-CSF), leukemia inhibitory factor (LIF), human growth hormone (hGH), ciliary neurotrophic factor (CNTF), leptin, oncostatin M, interleukin-6 (IL-6) and interleukin-12 (IL-12), erythropoietin (EPO), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), Flt3 ligand and stem cell factor (SCF).
- ), interferon alpha-2a (IFNα
-
4. The modified cytokine of claim 1, that is an interferon.
-
5. The modified cytokine of claim 1, that is an interferon α
- -2b (IFNα
-2b), interferon α
-2a (IFNα
-2a), interferon α
-2c (IFNα
-2c) or an interferon having the sequence set forth in SEQ ID No. 232.
- -2b (IFNα
-
6. A modified cytokine of claim 4, that is IFNα
- -2b or IFNα
-2a or IFNα
-2C selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID No.1 or 182, corresponding to the replacement of;
L by V at position 3;
L by I at position 3;
P by S at position 4;
P by A at position 4;
R by H at position 12;
R by Q at position 12;
R by H at position 13;
R by Q at position 13;
M by V at position 16;
M by I at position 16;
R by H at position 22;
R by Q at position 22;
R or K by H at position 23;
R or K by Q at position 23;
F by I at position 27;
F by V at position 27;
L by V at position 30;
L by I at position 30;
K by Q at position 31;
K by T at position 31;
R by H at position 33;
R by Q at position 33;
E by Q at position 41;
E by H at position 41;
K by Q at position 49;
K by T at position 49;
E by Q at position 58;
E by H at position 58;
K by Q at position 70;
K by T at position 70;
E by Q at position 78;
E by H at position 78;
K by Q at position 83;
K by T at position 83;
Y by H at position 89;
Y by I at position 89;
E by Q at position 96;
E by H at position 96;
E by Q at position 107;
E by H at position 107;
P by S at position 109;
P by A at position 109;
L by V at position 110;
L by I at position 110;
M by V at position 111;
M by I at position 111;
E by Q at position 113;
E by H at position 113;
L by V at position 117;
L by I at position 117;
R by H at position 120;
R by Q at position 120;
K by Q at position 121;
K by T at position 121;
R by H at position 125;
R by Q at position 125;
L by V at position 128;
L by I at position 128;
K by Q at position 131;
K by T at position 131;
E by Q at position 132;
E by H at position 132;
K by Q at position 133;
K by T at position 133;
K by Q at position 134;
K by T at position 134;
Y by H at position 135;
Y by I at position 135;
P by S at position 137;
P by A at position 137;
M by V at position 148;
M by I at position 148;
R by H at position 149;
R by Q at position 149;
E by Q at position 159;
E by H at position 159;
L by V at position 161;
L by I at position 161;
R by H at position 162;
R by Q at position 162;
K by Q at position 164;
K by T at position 164;
E by Q at position 165; and
E by H at position 165,wherein residue 1 corresponds to residue 1 of the mature IFNα
-2b or IFNα
-2a cytokine set forth in SEQ ID NOS;
1 or 182.
- -2b or IFNα
-
7. The modified cytokine of claim 6, wherein:
-
the protein is human;
has more resistance to proteolysis than the unmodified protein; and
the protein is selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
1 or 182, corresponding to;
F by V at position 27;
R by H at position 33;
E by Q at position 41;
E by H at position 41;
E by Q at position 58;
E by H at position 58;
E by Q at position 78;
E by H at position 78;
Y by H at position 89;
E by Q at position 107;
E by H at position 107;
P by A at position 109;
L by V at position 110;
M by V at position 111;
E by Q at position 113;
E by H at position 113;
L by V at position 117;
L by I at position 117;
K by Q at position 121;
K by T at position 121;
R by H at position 125;
R by Q at position 125;
K by Q at position 133;
K by T at position 133;
E by Q at position 159 and E by H at position 159.
-
-
8. A modified IFNα
- -2b or IFNα
-2a cytokine of claim 5 selected from the group consisting of proteins comprising one or more sets of dual-amino acid replacements in SEQ ID NOS;
1 or 182, corresponding to;
D by N at position 2 and P by S at position 4;
D by N at position 2 and P by T at position 4;
L by N at position 3 and Q by S at position 5;
L by N at position 3 and Q by T at position 5;
P by N at position 4 and T by S at position 6;
P by N at position 4 and T by T at position 6;
Q by N at position 5 and H by S at position 7;
Q by N at position 5 and H by T at position 7;
T by N at position 6 and S by S at position 8;
T by N at position 6 and S by T at position 8;
H by N at position 7 and L by S at position 9;
H by N at position 7 and L by T at position 9;
S by N at position 8 and G by S at position 10;
S by N at position 8 and G by T at position 10;
L by N at position 9 and S by S at position 11;
L by N at position 9 and S by T at position 11;
M by N at position 21 and K by S at position 23;
M by N at position 21 and K by T at position 23;
R by N at position 22 and I by S at position 24;
R by N at position 22 and I by T at position 24;
R or K by N at position 23 and S by S at position 25;
R or K by N at position 23 and S by T at position 25;
I by N at position 24 and L by S at position 26;
I by N at position 24 and L by T at position 26;
S by N at position 25 and F by S at position 27;
S by N at position 25 and F by T at position 27;
L by N at position 26 and S by S at position 28;
L by N at position 26 and S by T at position 28;
S by N at position 28 and L by S at position 30;
S by N at position 28 and L by T at position 30;
L by N at position 30 and D by S at position 32;
L by N at position 30 and D by T at position 32;
K by N at position 31 and R by S at position 33;
K by N at position 31 and R by T at position 33;
D by N at position 32 and H by S at position 34;
D by N at position 32 and H by T at position 34;
R by N at position 33 and D by S at position 35;
R by N at position 33 and D by T at position 35;
H by N at position 34 and F by S at position 36;
H by N at position 34 and F by T at position 36;
D by N at position 35 and G by S at position 37;
D by N at position 35 and G by T at position 37;
F by N at position 36 and F by S at position 38;
F by N at position 36 and F by T at position 38;
G by N at position 37 and P by S at position 39;
G by N at position 37 and P by T at position 39;
F by N at position 38 and Q by S at position 40;
F by N at position 38 and Q by T at position 40;
P by N at position 39 and E by S at position 41;
P by N at position 39 and E by T at position 41;
Q by N at position 40 and E by S at position 42;
Q by N at position 40 and E by T at position 42;
E by N at position 41 and F by S at position 43;
E by N at position 41 and F by T at position 43;
E by N at position 42 and G by S at position 44;
E by N at position 42 and G by T at position 44;
F by N at position 43 and N by S at position 45;
F by N at position 43 and N by T at position 45;
G by N at position 44 and Q by S at position 46;
G by N at position 44 and Q by T at position 46;
N by N at position 45 and F by S at position 47;
N by N at position 45 and F by T at position 47;
Q by N at position 46 and Q by S at position 48;
Q by N at position 46 and Q by T at position 48;
F by N at position 47 and K by S at position 49;
F by N at position 47 and K by T at position 49;
Q by N at position 48 and A by S at position 50;
Q by N at position 48 and A by T at position 50;
K by N at position 49 and E by S at position 51;
K by N at position 49 and E by T at position 51;
A by N at position 50 and T by S at position 52;
A by N at position 50 and T by T at position 52;
S by N at position 68 and K by S at position 70;
S by N at position 68 and K by T at position 70;
K by N at position 70 and S by S at position 72;
K by N at position 70 and S by T at position 72;
A by N at position 75 and D by S at position 77;
A by N at position 75 and D by T at position 77;
D by N at position 77 and T by S at position 79;
D by N at position 77 and T by T at position 79;
I by N at position 100 and G by S at position 102;
I by N at position 100 and G by T at position 102;
Q by N at position 101 and V by S at position 103;
Q by N at position 101 and V by T at position 103;
G by N at position 102 and G by S at position 104;
G by N at position 102 and G by T at position 104;
V by N at position 103 and V by S at position 105;
V by N at position 103 and V by T at position 105;
G by N at position 104 and T by S at position 106;
G by N at position 104 and T by T at position 106;
V by N at position 105 and E by S at position 107;
V by N at position 105 and E by T at position 107;
T by N at position 106 and T by S at position 108;
T by N at position 106 and T by T at position 108;
E by N at position 107 and P by S at position 109;
E by N at position 107 and P by T at position 109;
T by N at position 108 and I by S at position 110;
T by N at position 108 and I by T at position 110;
K by N at position 134 and S by S at position 136;
K by N at position 134 and S by T at position 136;
S by N at position 154 and N by S at position 156;
S by N at position 154 and N by T at position 156;
T by N at position 155 and L by S at position 157;
T by N at position 155 and L by T at position 157;
N by N at position 156 and Q by S at position 158;
N by N at position 156 and Q by T at position 158;
L by N at position 157 and E by S at position 159;
L by N at position 157 and E by T at position 159;
Q by N at position 158 and S by S at position 160;
Q by N at position 158 and S by T at position 160;
E by N at position 159 and L by S at position 161;
E by N at position 159 and L by T at position 161;
S by N at position 160 and R by S at position 162;
S by N at position 160 and R by T at position 162;
L by N at position 161 and S by S at position 163;
L by N at position 161 and S by T at position 163;
R by N at position 162 and K by S at position 164;
R by N at position 162 and K by T at position 164;
S by N at position 163 and E by S at position 165; and
S by N at position 163 and E by T at position 165, wherein residue 1 corresponds to residue 1 of the mature IFNα
-2b or IFNα
-2a cytokine set forth in SEQ ID NOS;
1 or 182.
- -2b or IFNα
-
9. A modified IFNα
- -2b or IFNα
-2a mutant cytokine of claim 5 selected from the group consisting of proteins comprising one or more sets of dual amino acid replacements in SEQ ID NOS;
1 or 182, corresponding to;
Q by N at position 5 and H by S at position 7;
P by N at position 39 and E by S at position 41;
P by N at position 39 and E by T at position 41;
Q by N at position 40 and E by S at position 42;
Q by N at position 40 and E by T at position 42;
E by N at position 41 and F by S at position 43;
E by N at position 41 and F by T at position 43;
F by N at position 43 and N by S at position 45;
G by N at position 44 and Q by T at position 46;
N by N at position 45 and F by S at position 47;
N by N at position 45 and F by T at position 47;
Q by N at position 46 and Q by S at position 48;
F by N at position 47 and K by S at position 49;
F by N at position 47 and K by T at position 49;
I by N at position 100 and G by S at position 102;
I by N at position 100 and G by T at position 102;
V by N at position 105 and E by S at position 107;
V by N at position 105 and E by T at position 107;
T by N at position 106 and T by S at position 108;
T by N at position 106 and T by T at position 108;
E by N at position 107 and P by S at position 109;
E by N at position 107 and P by T at position 109;
L by N at position 157 and E by S at position 159;
L by N at position 157 and E by T at position 159;
E by N at position 159 and L by S at position 161; and
E by N at position 159 and L by T at position 161.
- -2b or IFNα
-
10. A modified cytokine of claim 5, further comprising one or more pseudo-wild type mutations.
-
11. The modified cytokine of claim 10 that is IFNα
- -2b or IFNα
-2a.
- -2b or IFNα
-
12. A modified IFNα
- -2b or IFNα
-2a cytokine of claim 11, comprising one or more pseudo-wild type mutations at amino acid positions of IFNα
-2b or IFNα
-2a corresponding to SEQ ID NOS;
1 or 182, amino acid residues;
9, 10, 17, 20, 24, 25, 35, 37, 41, 52, 54, 56, 57, 58, 60, 63, 64, 65, 76, 89, and 90, wherein the mutations are selected from the group consisting of one or more of insertions, deletions and replacements of the native amino acid residue(s), wherein residue 1 corresponds to residue 1 of the mature IFNα
-2b or IFNα
-2a protein set forth in SEQ ID NOS;
1 or 182.
- -2b or IFNα
-
13. A modified IFNα
- -2b or IFNα
-2a cytokine of claim 11, comprising one wherein the pseudo-wild type replacements are one or more mutations in SEQ ID No. 1 or 182 corresponding to;
P by A at position 4;
Q by A at position 5,T by A at position 6;
L by A at position 9,LG by A at position 10;
L by A at position 17,Q by A at position 20;
I by A at position 24,S by A at position 25;
D by A at position 35,G by A at position 37;
G by A at position 39;
E by A at position 41;
E by A at position 42E by A at position 51;
T by A at position 52,P by A at position 54;
V by A at position 55L by A at position 56;
H by A at position 57,E by A at position 58;
I by A at position 60,I by A at position 63;
F by A at position 64,N by A at position 65;
W by A at position 76,D by A at position 77;
E by A at position 78L by A at position 81;
Y by A at position 85Y by A at position 89;
Q by A at position 90G by A at position 104;
L by A at position 110S by A at position 115 and E by A at position 146.
- -2b or IFNα
-
14. A modified cytokine of claim 5, comprising one or more pseudo-wild type mutations at amino acid positions of IFNα
- -2b, IFNα
-2c or a protein having the sequence set forth in SEQ ID No. 232 corresponding amino acid residues;
4, 5, 6, 9, 10, 17, 20, 24, 25, 35, 37, 39, 41, 42, 51, 52, 54, 56, 57, 58, 60, 63, 64, 65, 76, 77, 78, 81, 85, 89, 90, 104, 110, 115 and 146 to SEQ ID No. 1, 182 or 232, wherein the mutations are selected from the group consisting of one or more of insertions, deletions and replacements of the native amino acid residue(s), wherein residue 1 corresponds to residue 1 of the mature interferon set forth in SEQ ID No.1, 182 or 232.
- -2b, IFNα
-
15. The modified cytokin of claim 14, wherein the pseudowild type replacements are one or more mutations selected from:
-
P by A at position 4;
Q by A at position 5;
T by A at position 6;
L by A at position 9;
LG by A at position 10;
L by A at position 17;
Q by A at position 20;
I by A at position 24;
S by A at position 25;
D by A at position 35;
G by A at position 37;
G by A at position 39;
E by A at position 41;
E by A at position 42;
E by A at position 51;
T by A at position 52;
P by A at position 54;
V by A at position 55;
L by A at position 56;
H by A at position 57;
E by A at position 58;
I by A at position 60;
I by A at position 63;
F by A at position 64;
N by A at position 65;
W by A at position 76;
D by A at position 77;
E by A at position 78;
L by A at position 81;
Y by A at position 85;
Y by A at position 89, Q by A at position 90;
G by A at position 104;
L by A at position 110;
S by A at position 115 and E by A at position 146, wherein the positions correspond to SEQ ID No. 1, 182, 185 or 232.
-
-
16. A modified cytokine of claim 5 that has increased antiviral activity compared to the unmodified cytokine.
-
17. The modified cytokine of claim 16, wherein antiviral activity is assessed by measuring replication by reverse transcription quantification PCR (RT-qPCR).
-
18. A modified cytokine of claim 5 that has more antiviral activity than antiproliferative activity compared to the unmodified cytokine.
-
19. The modified cytokine of claim 18, wherein antiproliferative activity is assessed by measuring cell proliferation in the presence of the cytokine.
-
20. A modified cytokine of claim 5 that that binds to an IFN receptor, but exhibits decreased antiviral activity and decreased antiproliferative activity relative to its receptor binding activity when compared to the unmodified cytokine.
-
21. A modified cytokine of claim 1, comprising two or more mutations.
-
22. The modified cytokine of claim 21 that is a modified IFNα
- -2b cytokine.
-
23. A modified cytokine of claim 1, wherein the cytokine comprises the sequence of amino acids set forth in any of SEQ ID Nos 2 through 181, wherein the arginine at position 23 is replaced with a lysine.
-
24. A modified cytokine of any claim 1 selected from the group consisting of interleukin-10 (IL-10), interferon beta (IFNβ
- ), interferon alpha (IFNα
), interferon gamma (IFN-y), granulocyte colony stimulating factor (G-CSF), leukemia inhibitory factor (LIF), human growth hormone (hGH), ciliary neurotrophic factor (CNTF), leptin, oncostatin M, interleukin-6 (IL-6) and interleukin-12 (IL-12), erythropoietin (EPO), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), Flt3 ligand and stem cell factor (SCF).
- ), interferon alpha (IFNα
-
25. A collection of the modified cytokines of claim 1, wherein the modified cytokines contain one or a plurality of mutations.
-
26. A nucleic acid molecule encoding a modified cytokine of claim 1.
-
27. A vector comprising a nucleic acid molecule of claim 26.
-
28. A eukaryotic cell, comprising the vector of claim 27.
-
29. A collection of nucleic acid molecules comprising a plurality of the molecules of claim 26.
-
30. A collection of nucleic acid molecules comprising a plurality of the vectors of claim 27.
-
31. A method for expression of a modified cytokine, comprising:
-
introducing a nucleic acid of claim 26 into a host; and
culturing the cell, under conditions and in which the modified encoded cytokines are expressed.
-
-
32. The method of claim 31, wherein the nucleic acid is introduced into a host cell.
-
33. The method of claim 31, wherein the cytokine is a modified IFNα
- -2b, IFNα
-2a cytokine IFNα
-2c or interferon of SEQ ID No. 232.
- -2b, IFNα
-
34. The method of claim 31, wherein the host is a eukaryotic host cell.
-
35. The method of claim 34, wherein the cytokine is glycosylated.
-
36. The method of claim 31, wherein expression is effected in vivo.
-
37. The method of claim 31, wherein expression is effected in vitro.
-
38. The method of claim 31, wherein expression is effected in a cell-free system.
-
39. A modified cytokine claim 2, comprising two or more mutations.
-
40. A pharmaceutical composition, comprising a cytokine of claim 1 in a pharmaceutically acceptable carrier.
-
41. A modified cytokine of claim 5 that exhibits greater resistance to proteolysis compared to the unmodified cytokine, comprising one or more amino acid replacements at one or more positions on the cytokine corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of the IFNα
- -2b or IFNα
-2a or IFNα
-2c or consensus IFNα
of SEQ ID No. 232.
- -2b or IFNα
-
42. A modified cytokine of claim 41, wherein the resistance to proteolysis is measured by mixing it with a protease in vitro, incubation with blood or incubation with serum.
-
43. A modified cytokine of claim 1 that is a structural homolog of IFNα
- -2b, comprising one or more amino acid replacements in the cytokine structural homolog at positions corresponding to the 3-dimensional-structurally-similar modified positions within the 3-D structure of the modified IFNα
-2b or IFNα
-2a or IFNα
2c or an interferon of SEQ ID No. 232.
- -2b, comprising one or more amino acid replacements in the cytokine structural homolog at positions corresponding to the 3-dimensional-structurally-similar modified positions within the 3-D structure of the modified IFNα
-
44. A modified cytokine of claim 43, wherein the homolog has increased resistance to proteolysis compared to its unmodified cytokine counterpart, wherein the resistance to proteolysis is measured by mixture with a protease in vitro, incubation with blood or incubation with serum.
-
45. The cytokine of claim 44 that is an IFNα
- cytokine.
-
46. The cytokine of claim 45, selected from the group consisting of IFNα
- -2a, IFNα
-c, IFNα
-2c, IFNα
-d, IFNα
-5, IFNα
-6, IFNα
-4, IFNα
-4b, IFNα
-I, IFNα
-J, IFNα
-H, IFNα
-F, IFNα
-8, and IFNα
-consensus cytokine.
- -2a, IFNα
-
47. A modified cytokine of claim 1 that is modified IFNα
- -2a cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO. 182 in the IFNα
-2a corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of unmodified IFNα
-2b, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFN alpha-2a.
- -2a cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO. 182 in the IFNα
-
48. The modified IFNα
- -2a of claim 47, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
182, corresponding to amino acid positions 41, 58, 78, 107, 117, 125, 133 and 159.
- -2a of claim 47, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
49. A modified IFNα
- -c cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO. 183 in the IFNα
-c corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFN alpha-c.
- -c cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO. 183 in the IFNα
-
50. The modified IFNα
- -c of claim 49, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
183, corresponding to amino acid positions 41, 59, 79, 108, 118, 126, 134 and 160.
- -c of claim 49, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
51. A modified IFNα
- -c, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
185 in the IFNα
-2c corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-2c.
- -c, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
52. The modified IFNα
- -2c cytokine of claim 51, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
185, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134 and 160.
- -2c cytokine of claim 51, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
53. A modified IFNα
- -d cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
186 in the IFNα
-d corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-d.
- -d cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
54. The IFNα
- -d modified cytokine of claim 53, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
186, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134 and 160.
- -d modified cytokine of claim 53, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
55. A modified IFNα
- -5 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
187 in the IFNα
-5 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-5.
- -5 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
56. The IFNα
- -5 modified cytokine of claim 55, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
187, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134and 160.
- -5 modified cytokine of claim 55, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
57. A modified IFNα
- -6 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
188 in the IFNα
-6 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-6.
- -6 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
58. The IFNα
- -6 modified cytokine of claim 57, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
188, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134 and 160.
- -6 modified cytokine of claim 57, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
59. A modified IFNα
- -4 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
189 in the IFNα
-4 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-4.
- -4 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
60. The IFNα
- -4 modified cytokine of claim 59, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
189, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134 and 160.
- -4 modified cytokine of claim 59, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
61. A modified IFNα
- -4b cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
190 in the IFNα
-4b corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-4b.
- -4b cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
62. The IFNα
- -4b modified cytokine of claim 61, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
190, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134 and 160.
- -4b modified cytokine of claim 61, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
63. A modified IFNα
- -I cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
191 in the IFNα
-I corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-I.
- -I cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
64. The IFNα
- -I modified cytokine of claim 63, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
191, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134 and 160.
- -I modified cytokine of claim 63, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
65. A modified IFNα
- -J cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
192 in the IFNα
-J corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-J.
- -J cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
66. The IFNα
- -J modified cytokine of claim 65, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
192, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134and 160.
- -J modified cytokine of claim 65, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
67. A modified IFNα
- -H cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
193 in the IFNα
-H corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-H.
- -H cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
68. The IFNα
- -H modified cytokine of claim 67, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
193, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134 and 160.
- -H modified cytokine of claim 67, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
69. An IFNα
- -F cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
194 in the IFNα
-F corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-F.
- -F cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
70. The IFNα
- -F modified cytokine of claim 69, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
194, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134and 160.
- -F modified cytokine of claim 69, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
71. An IFNα
- -8 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
195 in the IFNα
-8 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-8.
- -8 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
72. The IFNα
- -8 modified cytokine of claim 71, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
195, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134 and 160.
- -8 modified cytokine of claim 71, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
73. An IFNα
- -consensus cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
232 in the IFNα
-consensus cytokine corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNα
-consensus.
- -consensus cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
74. The modified cytokine of claim 1 that is an IFNα
- -consensus cytokine, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
232, corresponding to amino acid positions 27, 33, 41, 59, 79, 90, 108, 110, 111, 112, 114, 118, 122, 126, 134and 160.
- -consensus cytokine, that is human and is selected from the group consisting of cytokines comprising one or more single amino acid replacements in SEQ ID NO;
-
75. A modified IFNβ
- cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
196 in the IFNα
-β
cytokine corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNβ
.
- cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
76. A modified IFNβ
- cytokine of claim 1, comprising mutations at one or more amino acid residues of IFNβ
corresponding to SEQ ID NO;
196 at positions corresponding to;
39, 42, 45, 47, 52, 67, 71, 73, 81, 107, 108, 109, 110, 111, 113, 116, 120, 123, 124, 128, 130, 134, 136, 137, 163 and 165, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
- cytokine of claim 1, comprising mutations at one or more amino acid residues of IFNβ
-
77. The modified IFNβ
- cytokine of claim 75, wherein the replacements are selected from the group consisting of amino acid sustitutions in SEQ ID NO;
196 corresponding to;
D by Q at position 39, D by H at position 39, D by G at position 39, E by Q at position 42, E by H at position 42, K by Q at position 45, K by T at position 45, K by S at position 45, K by H at position 45, L by V at position 47, L by I at position 47, L by T at position 47, L by Q at position 47, L by H at position 47, L by A at position 47, K by Q at position 52, K by T at position 52, K by S at position 52, K by H at position 52, F by I at position 67, F by V at position 67, R by H at position 71, R by Q at position 71, D by H at position 73, D by G at position 73, D by Q at position 73, E by Q at position 81, E by H at position 81, E by Q at position 107, E by H at position 107, K by Q at position 108, K by T at position 108, K by S at position 108, K by H at position 108, E by Q at position 109, E by H at position 109, D by Q at position 110, D by H at position 110, D by G at position 110, F by I at position 111, F by V at position 111, R by H at position 113, R by Q at position 113, L by V at position 116, L by I at position 116, L by T at position 116, L by Q at position 116, L by H at position 116, L by A at position 116, L by V at position 120, L by I at position 120, L by T at position 120, L by Q at position 120, L by H at position 120, L by A at position 120, K by Q at position 123, K by T at position 123, K by S at position 123, K by H at position 123, R by H at position 124,, R by Q at position 124, R by H at position 128, R by Q at position 128, L by V at position 130, L by I at position 130, L by T at position 130, L by Q at position 130, L by H at position 130, L by A at position 130, K by Q at position 134, K by T at position 134, K by S at position 134, K by H at position 134, K by Q at position 136, K by T at position 136, K by S at position 136,, K by H at position 136, E by Q at position 137, E by H at position 137, Y by H at position 163, Y by I at position 1631, R by H at position 165, R by Q at position 165, wherein the first amino acid listed is substituted by the second at the position indicated.
- cytokine of claim 75, wherein the replacements are selected from the group consisting of amino acid sustitutions in SEQ ID NO;
-
78. A modified cytokine that is an IFNβ
- -1 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
197 in the IFNβ
-1 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNβ
-1.
- -1 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
79. A modified cytokine of claim 4 that is an IFNβ
- -1 cytokine, comprising mutations at one or more amino acid residues of IFNβ
-1 corresponding to SEQ ID NO;
197 at positions 39, 42, 45, 47, 52, 67, 71, 73, 81, 107, 108, 109, 110, 111, 113, 116, 120, 123, 124, 128, 130, 134, 136, 137, 163 and 165, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
- -1 cytokine, comprising mutations at one or more amino acid residues of IFNβ
-
80. A modified cytokine that is an IFNβ
- -2a cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
198 in the IFNβ
-2a corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNβ
-2a.
- -2a cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO;
-
81. A modified cytokine of claim 4 that is an IFNβ
- -2a cytokine, comprising mutations at one or more amino acid residues of IFNβ
-2a corresponding to SEQ ID NO;
198 at positions 39, 42, 45, 47, 52, 67, 71, 73, 81, 107, 108, 109, 110, 111, 113, 116, 120, 123, 124, 128, 130, 134, 136, 137, 163 and 165, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
- -2a cytokine, comprising mutations at one or more amino acid residues of IFNβ
-
82. A modified IFN-gamma cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 199 in the IFN-gamma corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFN-gamma.
- 199 in the IFN-gamma corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-
83. A modified cytokine of claim 4 that is an IFN-gamma cytokine, comprising mutations at one or more amino acid residues of IFN-gamma corresponding to SEQ ID NO:
- 199 at positions 33, 37, 40, 41, 42, 58, 61, 64, 65 and 66, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s). {circumflex over (
)}C
- 199 at positions 33, 37, 40, 41, 42, 58, 61, 64, 65 and 66, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s). {circumflex over (
-
84. The modified IFN-gamma cytokine of claim 82, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 199 corresponding to;
- 199 corresponding to;
-
85. A modified IL-10 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 200 in the IL-10 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IL-10.
- 200 in the IL-10 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-
87. The modified IL-10 cytokine of claim 85, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 200 corresponding to;
- 200 corresponding to;
-
88. A modified erythropoietin cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 201 in the erythropoietin corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified erythropoietin.
- 201 in the erythropoietin corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-
89. A modified erythropoietin of claim 88, comprising mutations at one or more amino acid residues of erythropoietin corresponding to SEQ ID NO:
- 201 at positions 43, 45, 48, 49, 52, 53, 55, 72, 75, 76, 123, 129, 130, 131, 162, and 165, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
90. The modified erythropoietin cytokine of claim 88, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 201 corresponding to;
- 201 corresponding to;
-
91. A modified GM-CSF cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 202 in the GM-CSF corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of erythropoietin modified cytokines of claim 88, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified GM-CSF.
-
92. A modified cytokine of claim 91 that is a GM-CSF cytokine, comprising mutations at one or more amino acid residues of GM-CSF corresponding to SEQ ID NO:
- 202 at positions 38, 41, 45, 46, 48, 49, 51, 60, 63, 67, 92, 93, 119, 120, 123, and 124, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
93. The modified GM-CSF cytokine of claim 91, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 202 corresponding to;
- 202 corresponding to;
-
94. A modified Flt3 ligand cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 203 in the Flt3 ligand corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of erythropoietin modified cytokine of claim 88, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified Flt3 ligand.
-
95. A modified Flt3 ligand cytokine of claim 94, comprising mutations at one or more amino acid residues of Flt3 ligand corresponding to SEQ ID NO:
- 203 at positions 3, 40, 42, 43, 55, 58, 59, 61, 89, 90, 91, 95, and 96, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
96. The modified Flt3 ligand cytokine of claim 94, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 203 corresponding to;
- 203 corresponding to;
-
97. A modified IL-2 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 204 in the IL-2 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of erythropoietin modified cytokines of claim 88, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IL-2.
-
98. A modified IL-2 cytokine of claim 97, comprising mutations at one or more amino acid residues of IL-2 corresponding to SEQ ID NO:
- 204 at positions 43, 45, 48, 49, 52, 53, 60, 61, 65, 67, 68, 72, 100, 103, 104, 106, 107, 109, 110, and 132, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
99. The modified IL-2 cytokine of claim 97, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 204 corresponding to;
- 204 corresponding to;
-
100. A modified IL-3 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 205 in the IL-3 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of erythropoietin modified cytokines of claim 88, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IL-3.
-
101. A modified IL-3 cytokine of claim 100, comprising mutations at one or more amino acid residues of IL-3 corresponding to SEQ ID NO:
- 205;
37, 43, 46, 59, 63, 66, 96, 100, 101, and 103, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
- 205;
-
102. The modified IL-3 cytokine of claim 100, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 205 corresponding to;
- 205 corresponding to;
-
103. A modified SCF cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 206 in the SCF corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of erythropoietin modified cytokines of claim 88, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified SCF.
-
104. A modified SCF cytokine of claim 103, comprising mutations at one or more amino acid residues of SCF corresponding to SEQ ID NO:
- 206;
27, 31, 34, 37, 54, 58, 61, 62, 63, 96, 98, 99, 100, 102, 103, 106, 107, 108, 109, 134, and 137, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
- 206;
-
105. The modified SCF cytokine of claim 103, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 206 corresponding to;
- 206 corresponding to;
-
106. A modified IL-4 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 207 in the IL-4 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of erythropoietin modified cytokines of claim 88, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IL-4.
-
107. A modified IL-4 cytokine of claim 106, comprising mutations at one or more amino acid residues of IL-4 corresponding to SEQ ID NO:
- 207;
26, 37, 53, 60, 61, 64, 66, 100, 102, 103, and 126, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
- 207;
-
108. The modified IL-4 cytokine of claim 106, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 207 corresponding to;
- 207 corresponding to;
-
109. A modified IL-5 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 208 in the IL-5 cytokine corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of erythropoietin modified cytokines of claim 88, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IL-5.
-
110. A modified IL-5 cytokine of claim 109, comprising mutations at one or more amino acid residues of IL-5 corresponding to SEQ ID NO:
- 208 at positions 32, 34, 39, 46, 47, 56, 84, 85, 88, 89, 90, 102, 110, and 111, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
111. The modified IL-5 cytokine of claim 109, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 208 corresponding to;
- 208 corresponding to;
-
112. A modified IL-13 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 209 of an IL-13 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of erythropoietin modified cytokines of claim 88, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IL-13.
-
113. A modified IL-13 cytokine of claim 112, comprising mutations at one or more amino acid residues of IL-13 corresponding to SEQ ID NO:
- 209 at positions 32, 34, 38, 48, 79, 82, 85, 86, 88, 107, 108, 110, and 111, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
114. The modified IL-13 cytokine of claim 112, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 209 corresponding to;
- 209 corresponding to;
-
115. A modified G-CSF cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 210 in the G-CSF corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-2b modified cytokines of claim 5, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified G-CSF.
- 210 in the G-CSF corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNα
-
116. A modified G-CSF cytokine of claim 115, comprising mutations at one or more amino acid residues of G-CSF corresponding to SEQ ID NO:
- 210 at positions 61, 63, 68, 72, 86, 96, 100, 101, 131, 133, 135, 147, 169, 172, and 177, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
117. The modified G-CSF cytokine of claim 115, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 210 corresponding to;
- 210 corresponding to;
-
118. A modified leptin cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 211 in the leptin corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of G-CSF modified cytokines of claim 115, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified leptin.
-
119. A modified leptin cytokine of claim 118, comprising mutations at one or more amino acid residues of leptin corresponding to SEQ ID NO:
- 211 at positions 43, 49, 99, 100, 104, 105, 107, 108, 141 and 142, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
120. The modified leptin cytokine of claim 118, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 211 corresponding to;
- 211 corresponding to;
-
121. A modified CNTF cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 212 in the CNTF corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of G-CSF modified cytokines of claim 115, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified CNTF.
-
122. A modified CNTF cytokine of claim 121, comprising mutations at one or more amino acid residues of CNTF corresponding to SEQ ID NO:
- 212 at positions 62, 64, 66, 67, 86, 89, 92, 100, 102, 104, 131, 132, 133, 135, 136, 138, 140, 143, 148, and 151, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
123. The modified CNTF cytokine of claim 121, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 212 corresponding to;
- 212 corresponding to;
-
124. A modified LIF cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 213 in the LIF corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of G-CSF modified cytokines of claim 115, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified LIF.
-
125. A modified LIF cytokine of claim 124, comprising mutations at one or more amino acid residues of LIF corresponding to SEQ ID NO:
- 213 at positions 69, 70, 85, 99, 102, 104, 106, 109, 137, 143, 146, 148, 149, 153, 154, and 156, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
126. The modified LIF cytokine of claim 124, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 213 corresponding to;
- 213 corresponding to;
-
127. A modified oncostatin M cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 214 in the oncostatin M corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of G-CSF modified cytokines of claim 115, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified oncostatin M.
-
128. A modified oncostatin M cytokine of claim 127, comprising mutations at one or more amino acid residues of oncostatin M corresponding to SEQ ID NO:
- 214 at positions 59, 60, 63, 65, 84, 87, 89, 91, 94, 97, 99, 100, 103, and 106, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
129. The modified oncostatin M cytokine of claim 127, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 214 corresponding to;
- 214 corresponding to;
-
130. A modified IL-12 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 215 in the IL-12 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of G-CSF modified cytokines of claim 115, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IL-12.
-
131. A modified IL-12 cytokine of claim 130, comprising mutations at one or more amino acid residues of IL-12 corresponding to SEQ ID NO:
- 215 at positions 56, 61, 66, 67, 68, 70, 72, 75, 78, 79, 82, 89, 92, 93, 107, 110, 111, 115, 117, 124, 125, 127, 128, 129, and 189, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
132. The modified IL-12 cytokine of claim 130, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 215 corresponding to;
- 215 corresponding to;
-
133. A modified hGH cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 216 in the hGH corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of G-CSF modified cytokines of claim 115, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified hGH.
-
134. A modified hGH cytokine of claim 133, comprising mutations at one or more amino acid residues of hGH corresponding to SEQ ID NO:
- 216 at positions 56, 59, 64, 65, 66, 88, 92, 94, 101, 129, 130, 133, 134, 140, 143, 145, 146, 147, 183, and 186, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
135. The modified hGH cytokine of claim 133, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 216 corresponding to;
- 216 corresponding to;
-
136. A modified IL-6 cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO:
- 217 in the IL-6 corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of G-CSF modified cytokines of claim 115, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IL-6.
-
137. A modified IL-6 cytokine of claim 136, comprising mutations at one or more amino acid residues of IL-6 corresponding to SEQ ID NO:
- 217 at position 64, 65, 66, 68, 69, 75, 77, 92, 98, 103, 105, 108, 133, 138, 139, 140, 149, 156, 178, and 181, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
138. The modified IL-6 cytokine of claim 136, wherein the replacements are selected from the group consisting of amino acid stitutions in SEQ ID NO:
- 217 corresponding to;
- 217 corresponding to;
-
139. The modified IFNα
- -2b cytokine of claim 5 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity to either inhibit viral replication or to stimulate cell proliferation in appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
140. The modified IFNα
- -2b cytokine of claim 5 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity to either inhibit viral replication in the appropriate cells or to stimulate cell proliferation of the appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
141. The modified IFNα
- -2b cytokine of claim 5 that has increased biological activity compared to the unmodified cytokine, wherein activity is assessed by measuring the capacity to either inhibit viral replication in the appropriate cells or to stimulate cell proliferation of the appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
142. The modified IFNα
- -2a cytokine of claim 47 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity to either inhibit viral replication or to stimulate cell proliferation in appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
143. The modified IFNα
- -2a cytokine of claim 47 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity to either inhibit viral replication in the appropriate cells or to stimulate cell proliferation of the appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
144. The modified IFNα
- -2a cytokine of claim 47 that has increased biological activity compared to the unmodified cytokine, wherein activity is assessed by measuring the capacity to either inhibit viral replication in the appropriate cells or to stimulate cell proliferation of the appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
145. The modified IFNα
- -c cytokine of claim 49 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
146. The modified IFNα
- -c cytokine of claim 49 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
147. The modified IFNα
- -c cytokine of claim 49 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
148. The modified IFNα
- -2c cytokine of claim 51 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
149. The modified IFNα
- -2c cytokine of claim 51 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
150. The modified IFNα
- -2c cytokine of claim 51 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
151. The modified IFNα
- -1d cytokine of claim 53 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
152. The modified IFNα
- -1d cytokine of claim 53 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
153. The modified IFNα
- -1d cytokine of claim 53 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
154. The modified IFNα
- -5 cytokine of claim 55 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
155. The modified IFNα
- -5 cytokine of claim 55 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
156. The modified IFNα
- -5 cytokine of claim 55 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
157. The modified IFNα
- -6 cytokine of claim 57 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
158. The modified IFNα
- -6 cytokine of claim 57 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
159. The modified IFNα
- -6 cytokine of claim 57 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
160. The modified IFNα
- -4 cytokine of claim 59 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
161. The modified IFNα
- -4 cytokine of claim 59 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
162. The modified IFNα
- -4 cytokine of claim 59 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
163. The modified IFNα
- -4b cytokine of claim 61 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
164. The modified IFNα
- -4b cytokine of claim 61 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
165. The modified IFNα
- -4b cytokine of claim 61 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
166. The modified IFNα
- -I cytokine of claim 63 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
167. The modified IFNα
- -I cytokine of claim 63 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
168. The modified IFNα
- -I cytokine of claim 63 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
169. The modified IFNα
- -J cytokine of claim 65 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
170. The modified IFNα
- -J cytokine of claim 65 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
171. The modified IFNα
- -J cytokine of claim 65 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
172. The modified IFNα
- -H cytokine of claim 67 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
173. The modified IFNα
- -H cytokine of claim 67 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
174. The modified IFNα
- -H cytokine of claim 67 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
175. The modified IFNα
- -F cytokine of claim 69 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
176. The modified IFNα
- -F cytokine of claim 69 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
177. The modified IFNα
- -F cytokine of claim 69 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
178. The modified IFNα
- -8 cytokine of claim 71 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
179. The modified IFNα
- -8 cytokine of claim 71 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
180. The modified IFNα
- -8 cytokine of claim 71 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
181. The modified IFNα
- consensus cytokine of claim 73 that has increased stability compared to any of the aligned cytokines, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
182. The modified IFNα
- consensus cytokine of claim 73 that has decreased stability compared to any of the aligned cytokines, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
183. The modified IFNα
- consensus cytokine of claim 73 that has increased biological activity compared to any of the aligned cytokines, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
184. The modified IFNβ
- cytokine of claim 75 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
185. The modified IFNβ
- cytokine of claim 75 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
186. The modified IFNβ
- cytokine of claim 75 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
187. The modified IFN β
- -1 cytokine of claim 78 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
188. The modified IFN β
- -1 cytokine of claim 78 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
189. The modified IFN β
- -1 cytokine of claim 78 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
190. The modified IFN β
- -2a cytokine of claim 80 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
191. The modified IFN β
- -2a cytokine of claim 80 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
192. The modified IFN β
- -2a cytokine of claim 80 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
193. The modified IFN-gamma cytokine of claim 82 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
194. The modified IFN-gamma cytokine of claim 82 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
195. The modified IFN-gamma cytokine of claim 82 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
196. The modified IL-10 cytokine of claim 85 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
197. The modified IL-10 cytokine of claim 85 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
198. The modified IL-10 cytokine of claim 85 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
199. The modified erythropoietin cytokine of claim 88 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
200. The modified erythropoietin cytokine of claim 88 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
201. The modified erythropoietin cytokine of claim 88 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
202. The modified GM-CSF cytokine of claim 91 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
203. The modified GM-CSF cytokine of claim 91 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
204. The modified GM-CSF cytokine of claim 91 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
205. The modified Flt3 ligand cytokine of claim 94 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
206. The modified Flt3 ligand cytokine of claim 94 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
207. The modified Flt3 ligand cytokine of claim 94 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
208. The modified IL-2 cytokine of claim 97 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
209. The modified IL-2 cytokine of claim 97 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
210. The modified IL-2 cytokine of claim 97 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
211. The modified IL-3 cytokine of claim 100 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
212. The modified IL-3 cytokine of claim 100 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
213. The modified IL-3 cytokine of claim 100 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
214. The modified SCF cytokine of claim 103 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
215. The modified SCF cytokine of claim 103 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
216. The modified SCF cytokine of claim 103 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
217. The modified IL-4 cytokine of claim 106 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
218. The modified IL-4 cytokine of claim 106 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
219. The modified IL-4 cytokine of claim 106 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
220. The modified IL-5 cytokine of claim 109 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
221. The modified IL-5 cytokine of claim 109 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
222. The modified IL-5 cytokine of claim 109 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
223. The modified IL-13 cytokine of claim 112 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
224. The modified IL-13 cytokine of claim 112 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
225. The modified IL-13 cytokine of claim 112 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
226. The modified G-CSF cytokine of claim 115 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
227. The modified G-CSF cytokine of claim 115 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
228. The modified G-CSF cytokine of claim 115 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
229. The modified leptin cytokine of claim 118 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
230. The modified leptin cytokine of claim 118 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
231. The modified leptin cytokine of claim 118 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
232. The modified CNTF cytokine of claim 121 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
233. The modified CNTF cytokine of claim 121 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
234. The modified CNTF cytokine of claim 121 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
235. The modified LIF cytokine of claim 124 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
236. The modified LIF cytokine of claim 124 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
237. The modified LIF cytokine of claim 124 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
238. The modified oncostatin M cytokine of claim 127 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
239. The modified oncostatin M cytokine of claim 127 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
240. The modified oncostatin M cytokine of claim 127 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
241. The modified IL-12 cytokine of claim 130 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
242. The modified IL-12 cytokine of claim 130 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
243. The modified IL-12 cytokine of claim 130 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
244. The modified hGH of claim 133 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
245. The modified hGH of claim 133 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
246. The modified hGH of claim 133 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
247. The modified IL-6 cytokine of claim 136 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
248. The modified IL-6 cytokine of claim 136 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
249. The modified IL-6 cytokine of claim 136 that has increased biological activity compared to the unmodified cytokine, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
279. A modified cytokine of claim 1 selected from the group consisting of modified cytokines comprising a sequence of amino acids set forth in any of SEQ ID Nos. 2-181, 233-1303 or a structural homolog thereof.
-
280. The modified cytokine of claim 279, selected from the group consisting of interleukin-10 (IL-10), interferon α
- , interferon β
, interferon y, granulocyte colony stimulating factor (G-CSF), leukemia inhibitory factor (LIF), human growth hormone (hGH), ciliary neurotrophic factor (CNTF), leptin, oncostatin M, interleukin-6 (IL-6) and interleukin-12 (IL-12), erythropoietin (EPO), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), Flt3 ligand and stem cell factor (SCF).
- , interferon β
-
306. A modified cytokine of claim 1 that is an IFNα
- -2b, IFNα
-2a, IFN-2c cytokine selected from the group consisting of proteins comprising one or more single amino acid replacements corresponding to the replacement of;
N by D at position 45;
D by G at position 94;
G by R at position 102;
A by G at position 139;
or any combination thereof.
- -2b, IFNα
-
307. A modified cytokine of claim 1 that is an IFNα
- -2b, IFNα
-2a, IFN-2c cytokine selected from selected from the group consisting of proteins comprising one or more single amino acid replacements in any of SEQ ID Nos. 1, 182, 185 or 232 or any combination thereof corresponding to the replacement;
L by V at position 3;
L by I at position 3;
P by S at position 4;
P by by S at position 4;
P by A at position 4;
R by H at position 12;
R by Q at position 12;
R by H at position 13;
R by Q at position 13;
M by V at position 16;
M by I at position 16;
R by H at position 22;
R by Q at position 22;
R or K by H at position 23;
R or K by Q at position 23;
F by I at position 27;
F by V at position 27;
L by V at position 30;
L by I at position 30;
K by Q at position 31;
K by T at position 31;
R by H at position 33;
R by Q at position 33;
E by Q at position 41;
E by H at position 41;
K by Q at position 49;
K by T at position 49;
E by Q at position 58;
E by H at position 58;
K by Q at position 70;
K by T at position 70;
E by Q at position 78;
E by H at position 78;
K by Q at position 83;
K by T at position 83;
Y by H at position 89;
Y by I at position 89;
E by Q at position 96;
E by H at position 96;
E by Q at position 107;
E by H at position 107;
P by S at position 109;
P by A at position 109;
L by V at position 110;
L by I at position 110;
M by V at position 111;
M by I at position 111;
E by Q at position 113;
E by H at position 113;
L by V at position 117;
L by I at position 117;
R by H at position 120;
R by Q at position 120;
K by Q at position 121;
K by T at position 121;
R by H at position 125;
R by Q at position 125;
L by V at position 128;
L by I at position 128;
K by Q at position 131;
K by T at position 131;
E by Q at position 132;
E by H at position 132;
K by Q at position 133;
K by T at position 133;
K by Q at position 134;
K by T at position 134;
Y by H at position 135;
Y by I at position 135;
P by S at position 137;
P by A at position 137;
M by V at position 148;
M by I at position 148;
R by H at position 149;
R by Q at position 149;
E by Q at position 159;
E by H at position 159;
L by V at position 161;
L by I at position 161;
R by H at position 162;
R by Q at position 162;
K by Q at position 164;
K by T at position 164;
E by Q at position 165; and
E by H at position 165 or any combination thereof, wherein residue 1 corresponds to residue 1 of the mature IFNα
-2b or IFNα
-2a cytokine set forth in SEQ ID NOS;
1 or 182.
- -2b, IFNα
-
308. A modified cytokine of claim 1 that is an IFNα
- -2b, IFNα
-2a, IFN-2c cytokine selected from selected from the group consisting of proteins comprising one or more single amino acid replacements in any of SEQ ID Nos. 1, 182, 185 or 232 or any combination thereof corresponding to the replacement L by V at position 3;
L by I at position 3;
P by S at position 4;
P by A at position 4;
R by H at position 12;
R by Q at position 12;
R by H at position 13;
R by Q at position 13;
M by V at position 16;
M by I at position 16;
R by H at position 22;
R by Q at position 22;
R or K by H at position 23;
R or K by Q at position 23;
F by I at position 27;
F by V at position 27;
L by V at position 30;
L by I at position 30;
K by Q at position 31;
K by T at position 31;
R by H at position 33;
R by Q at position 33;
E by Q at position 41;
E by H at position 41;
K by Q at position 49;
K by T at position 49;
E by Q at position 58;
E by H at position 58;
K by Q at position 70;
K by T at position 70;
E by Q at position 78;
E by H at position 78;
K by Q at position 83;
K by T at position 83;
Y by H at position 89;
Y by I at position 89;
E by Q at position 96;
E by H at position 96;
E by Q at position 107;
E by H at position 107;
P by S at position 109;
P by A at position 109;
L by V at position 110;
L by I at position 110;
M by V at position 111;
M by I at position 111;
E by Q at position 113;
E by H at position 113;
L by V at position 117;
L by I at position 117;
R by H at position 120;
R by Q at position 120;
K by Q at position 121;
K by T at position 121;
R by H at position 125;
R by Q at position 125;
L by V at position 128;
L by I at position 128;
K by Q at position 131;
K by T at position 131;
E by Q at position 132;
E by H at position 132;
K by Q at position 133;
K by T at position 133;
K by Q at position 134;
K by T at position 134;
Y by H at position 135;
Y by I at position 135;
P by S at position 137;
P by A at position 137;
M by V at position 148;
M by I at position 148;
R by H at position 149;
R by Q at position 149;
E by Q at position 159;
E by H at position 159;
L by V at position 161;
L by I at position 161;
R by H at position 162;
R by Q at position 162;
K by Q at position 164;
K by T at position 164;
E by Q at position 165;
E by H at position 165;
N by D at position 45;
D by G at position 94;
G by R at position 102; and
A by G at position 139, wherein residue 1 corresponds to residue 1 of the mature IFNα
-2b or IFNα
-2a cytokine set forth in SEQ ID No. 1 or 182.
- -2b, IFNα
-
309. The modified cytokine of claim 1, that is an interferon β
- (IFNβ
).
- (IFNβ
-
310. A modified IFN β
- cytokine of claim 309 selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
196, corresponding to the replacement of M by V at position 1, M by I at position 1, M by T at position 1, M by Q at position 1, M by A at position 1, L by V at position 5, L by I at position 5, L by T at position 5, L by Q at position 5, L by H at position 5, L by A at position 5, F by I at position 8, F by V at position 8, L by V at position 9, L by I at position 9, L by T at position 9, L by Q at position 9, L by H at position 9, L by A at position 9, R by H at position 11, R by Q at position 11, F by I at position 15, F by V at position 15, K by Q at position 19, K by T at position 19, K by S at position 19, K by H at position 19, W by S at position 22, W by H at position 22, N by H at position 25, N by S at position 25, N by Q at position 25, R by H position 27, R by Q position 27, L by V at position 28, L by I at position 28, L by T at position 28, L by Q at position 28, L by H at position 28, L by A at position 28, E by Q at position 29, E by H at position 29, Y by H at position 30, Y by I at position 30, L by V at position 32, L by I at position 32, L by T at position 32, L by Q at position 32, L by H at position 32, L by A at position 32, K by Q at position 33, K by T at position 33, K by S at position 33, K by H at position 33, R by H at position 35, R by Q at position 35, M by V at position 36, M by I at position 36, M by T at position 36, M by Q at position 36, M by A at position 36, D by Q at position 39, D by H at position 39, D by G at position 39, E by Q at position 42, E by H at position 42, K by Q at position 45, K by T at position 45, K by S at position 45, K by H at position 45, L by V at position 47, L by I at position 47, L by T at position 47, L by, Q at position 47, L by H at position 47, L by A at position 47, K by Q at position 52, K by T at position 52, K by S at position 52, K by H at position 52, F by I at position 67, F by V at position 67, R by H at position 71, R by Q at position 71, D by Q at position 73, D by H at position 73, D by G at position 73, E by Q at position 81, E by H at position 81, E by Q at position 85, E by H at position 85, Y by H at position 92, Y by I at position 92, K by Q at position 99, K by T at position 99, K by S at position 99, K by H at position 99, E by Q at position 103, E by H at position 103, E by Q at position 104, E by H at position 104, K by Q at position 105, K by T at position 105, K by S at position 105, K by H at position 105, E by Q at position 107, E by H at position 107, K by Q at position 108, K by T at position 108, K by S at position 108, K by H at position 108, E by Q at position 109, E by H at position 109, D by Q at position 110, D by H at position 110, D by G at position 110, F by I at position 111, F by V at position 111, R by H at position 113, R by Q at position 113, L by V at position 116, L by I at position 116, L by T at position 116, L by Q at position 116, L by H at position 116, L by A at position 116, L by V at position 120, L by I at position 120, L by T at position 120, L by Q at position 120, L by H at position 120, L by A at position 120, K by Q at position 123, K by T at position 123, K by S at position 123, K by H at position 123, R by H at position 124, R by Q at position 124, R by H at position 128, R by Q at position 128, L by V at position 130, L by I at position 130, L by T at position 130, L by Q at position 130, L by H at position 130, L by A at position 130, K by Q at position 134, K by T at position 134, K by S at position 134, K by H at position 134, K by Q at position 136, K by T at position 136, K by S at position 136, K by H at position 136, E by Q at position 137, E by H at position 137, Y by H at position 138, Y by I at position 138, R by H at position 152, R by Q at position 152, Y by H at position 155, Y by I at position 155, R by H at position 159, R by Q at position 159, Y by H at position 163, Y by I at position 163, R by H at position 165, R by Q at position 165, M by D at position 1, M by E at position 1, M by K at position 1, M by N at position 1, M by R at position 1, M by S at position 1, L by D at position 5, L by E at position 5, L by K at position 5, L by N at position 5, L by R at position 5, L by S at position 5, L by D at position 6, L by E at position 6, L by K at position 6, L by N at position 6, L by R at position 6, L by S at position 6, L by Q at position 6, L by T at position 6, F by E at position 8, F by K at position 8, F by R at position 8, F by D at position 8, L by D at position 9, L by E at position 9, L by K at position 9, L by N at position 9, L by R at position 9, L by S at position 9, Q by D at position 10, Q by E at position 10, Q by K at position 10, Q by N at position 10, Q by R at position 10, Q by S at position 10, Q by T at position 10, S by D at position 12, S by E at position 12, S by K at position 12, S by R at position 12, S by D at position 13, S by E at position 13, S by K at position 13, S by R at position 13, S by N at position 13, S by Q at position 13, S by T at position 13, N by D at position 14, N by E at position 14, N by K at position 14, N by Q at position 14, N by R at position 14, N by S at position 14, N by T at position 14, F by D at position 15, F by E at position 15, F by K at position 15, F by R at position 15, Q by D at position 16, Q by E at position 16, Q by K at position 16, Q by N at position 16, Q by R at position 16, Q by S at position 16, Q by T at position 16, C by D at position 17, C by E at position 17, C by K at position 17, C by N at position 17, C by Q at position 17, C by R at position 17, C by S at position 17, C by T at position 17, L by N at position 20, L by Q at position 20, L by R at position 20, L by S at position 20, L by T at position 20, L by D at position 20, L by E at position 20, L by K at position 20, W by D at position 22, W by E at position 22, W by K at position 22, W by R at position 22, Q by D at position 23, Q by E at position 23, Q by K at position 23, Q by R at position 23, L by D at position 24, L by E at position 24, L by K at position 24, L by R at position 24, W by D at position 79, W by E at position 79, W by K at position 79, W by R at position 79, N by D at position 80, N by E at position 80, N by K at position 80, N by R at position 80, T by D at position 82, T by E at position 82, T by K at position 82, T by R at position 82, I by D at position 83, I by E at position 83, I by K at position 83, I by R at position 83, I by N at position 83, I by Q at position 83, I by S at position 83, I by T at position 83, N by D at position 86, N by E at position 86, N by K at position 86, N by R at position 86, N by Q at position 86, N by S at position 86, N by T at position 86, L by D at position 87, L by E at position 87, L by K at position 87, L by R at position 87, L by N at position 87, L by Q at position 87, L by S at position 87, L by T at position 87, A by D at position 89, A by E at position 89, A by K at position 89, A by R at position 89, N by D at position 90, N by E at position 90, N by K at position 90, N by Q at position 90, N by R at position 90, N by S at position 90, N by T at position 90, V by D at position 91, V by E at position 91, V by K at position 91, V by N at position 91, V by Q at position 91, V by R at position 91, V by S at position 91, V by T at position 91, Q by D at position 94, Q by E at position 94, Q by Q at position 94, Q by N at position 94, Q by R at position 94, Q by S at position 94, Q by T at position 94, I by D at position 95, I by E at position 95, I by K at position 95, I by N at position 95, I by Q at position 95, I by R at position 95, I by S at position 95, I by T at position 95, H by D at position 97, H by E at position 97, H by K at position 97, H by N at position 97, H by Q at position 97, H by R at position 97, H by S at position 97, H by T at position 97, L by D at position 98, L by E at position 98, L by K at position 98, L by N at position 98, L by Q at position 98, L by R at position 98, L by S at position 98, L by T at position 98, V by D at position 101, V by E at position 101, V by K at position 101, V by N at position 101, V by Q at position 101, V by R at position 101, V by S at position 101, V by T at position 101, M by C at position 1, L by C at position 6, Q by C at position 10, S by C at position 13, Q by C at position 16, L by C at position 17, V by C at position 101, L by C at position 98, H by C at position 97, Q by C at position 94, V by C at position 91, N by C at position 90,wherein residue 1 corresponds to residue 1 of the mature IFNβ
cytokine set forth in SEQ ID NO;
196.
- cytokine of claim 309 selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
-
311. A modified cytokine of claim 1 that comprises one or more pseudo-wild type mutations.
-
312. The modified cytokine of claim 311 that is a modified IFNβ
- .
-
313. A modified IFNβ
- cytokine of claim 309 that has increased antiviral activity compared to the unmodified cytokine.
-
314. The modified IFNβ
- cytokine of claim 313, wherein antiviral activity is assessed by measuring replication by reverse transcription quantification PCR (RT-qPCR) or CPE (cythopathic effect).
-
315. A modified IFNα
- -2b or IFNα
-2a cytokine of claim 309 that has more antiviral activity than antiproliferative activity compared to the unmodified cytokine.
- -2b or IFNα
-
316. The cytokine of claim 315, wherein antiproliferative activity is assessed by measuring cell proliferation in the presence of the cytokine.
-
317. A modified IFNβ
- cytokine of claim 309 that binds to an IFN receptor, but exhibits when compared to unmodified IFNβ
, decreased antiviral activity and decreased antiproliferative activity relative to its receptor binding activity.
- cytokine of claim 309 that binds to an IFN receptor, but exhibits when compared to unmodified IFNβ
-
318. A modified cytokine of claim 1, comprising two or more mutations.
-
319. A pharmaceutical composition, comprising a cytokine of claim 1 in a pharmaceutically acceptable carrier.
-
320. A modified cytokine that exhibits greater resistance to proteolysis compared to the unmodified cytokine, comprising one or more amino acid replacements at one or more target positions on the cytokine corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of the IFNβ
- modified cytokines of claim 309.
-
321. A modified cytokine of claim 320, wherein the resistance to proteolysis is measured by mixing it with a protease in vitro, incubation with blood or incubation with serum.
-
322. A cytokine structural homolog of an IFNβ
- modified cytokine of claim 309, comprising one or more amino acid replacements in the cytokine structural homolog at positions corresponding to the 3-dimensional-structurally-similar modified positions within the 3-D structure of the modified IFNβ
.
- modified cytokine of claim 309, comprising one or more amino acid replacements in the cytokine structural homolog at positions corresponding to the 3-dimensional-structurally-similar modified positions within the 3-D structure of the modified IFNβ
-
323. A cytokine homolog of claim 322, wherein the homolog has increased resistance to proteolysis compared to its unmodified cytokine counterpart, wherein the resistance to proteolysis is measured by mixture with a protease in vitro, incubation with blood, or incubation with serum.
-
324. A modified IFNβ
- cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO. 196 in the IFNβ
corresponding to a structurally-related modified amino acid position within the 3-dimensional structure of IFNβ
modified cytokines of claim 309, wherein the replacements lead to greater resistance to proteases, as assessed by incubation with a protease or a with a blood lysate or by incubation with serum, compared to the unmodified IFNβ
.
- cytokine, comprising one or more amino acid replacements at one or more target positions in SEQ ID NO. 196 in the IFNβ
-
325. The modified IFNβ
- cytokine of claim 309 that has increased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity to either inhibit viral replication or to stimulate cell proliferation in appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
326. The modified IFNβ
- cytokine of claim 309 that has decreased stability compared to the unmodified cytokine, wherein stability is assessed by measuring residual biological activity to either inhibit viral replication in the appropriate cells or to stimulate cell proliferation of the appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
327. The modified IFNβ
- cytokine of claim 309 that has increased biological activity compared to the unmodified cytokine, wherein activity is assessed by measuring the capacity to either inhibit viral replication in the appropriate cells or to stimulate cell proliferation of the appropriate cells, after incubation with either mixtures of proteases, individual proteases, blood lysate or serum.
-
328. A modified of IFNβ
- cytokine of claim 309, selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
196, or any combination thereof, corresponding to the replacement of;
M by V at position 1, M by I at position 1, M by T at position 1, M by Q at position 1, M by A at position 1, L by V at position 5, L by I at position 5, L by T at position 5, L by Q at position 5, L by H at position 5, L by A at position 5, F by I at position 8, F by V at position 8, L by V at position 9, L by I at position 9, L by T at position 9, L by Q at position 9, L by H at position 9, L by A at position 9, R by H at position 11, R by Q at position 11, F by I at position 15, F by V at position 15, K by Q at position 19, K by T at position 19, K by S at position 19, K by H at position 19, W by S at position 22, W by H at position 22, N by H at position 25, N by S at position 25, N by Q at position 25, R by H position 27, R by Q position 27, L by V at position 28, L by I at position 28, L by T at position 28, L by Q at position 28, L by H at position 28, L by A at position 28, E by Q at position 29, E by H at position 29, Y by H at position 30, Y by I at position 30, L by V at position 32, L by I at position 32, L by T at position 32, L by Q at position 32, L by H at position 32, L by A at position 32, K by Q at position 33, K by T at position 33, K by S at position 33, K by H at position 33, R by H at position 35, R by Q at position 35, M by V at position 36, M by I at position 36, M by T at position 36, M by Q at position 36, M by A at position 36, D by Q at position 39, D by H at position 39, D by G at position 39, E by Q at position 42, E by H at position 42, K by Q at position 45, K by T at position 45, K by S at position 45, K by H at position 45, L by V at position 47, L by I at position 47, L by T at position 47, L by, Q at position 47, L by H at position 47, L by A at position 47, K by Q at position 52, K by T at position 52, K by S at position 52, K by H at position 52, F by I at position 67, F by V at position 67, R by H at position 71, R by Q at position 71, D by Q at position 73, D by H at position 73, D by G at position 73, E by Q at position 81, E by H at position 81, E by Q at position 85, E by H at position 85, Y by H at position 92, Y by I at position 92, K by Q at position 99, K by T at position 99, K by S at position 99, K by H at position 99, E by Q at position 103, E by H at position 103, E by Q at position 104, E by H at position 104, K by Q at position 105, K by T at position 105, K by S at position 105, K by H at position 105, E by Q at position 107, E by H at position 107, K by Q at position 108, K by T at position 108, K by S at position 108, K by H at position 108, E by Q at position 109, E by H at position 109, D by Q at position 110, D by H at position 110, D by G at position 110, F by I at position 111, F by V at position 111, R by H at position 113, R by Q at position 113, L by V at position 116, L by I at position 116, L by T at position 116, L by Q at position 116, L by H at position 116, L by A at position 116, L by V at position 120, L by I at position 120, L by T at position 120, L by Q at position 120, L by H at position 120, L by A at position 120, K by Q at position 123, K by T at position 123, K by S at position 123, K by H at position 123, R by H at position 124, R by Q at position 124, R by H at position 128, R by Q at position 128, L by V at position 130, L by I at position 130, L by T at position 130, L by Q at position 130, L by H at position 130, L by A at position 130, K by Q at position 134, K by T at position 134, K by S at position 134, K by H at position 134, K by Q at position 136, K by T at position 136, K by S at position 136, K by H at position 136, E by Q at position 137, E by H at position 137, Y by H at position 138, Y by I at position 138, R by H at position 152, R by Q at position 152, Y by H at position 155, Y by I at position 155, R by H at position 159, R by Q at position 159, Y by H at position 163, Y by I at position 163, R by H at position 165, R by Q at position 165, M by D at position 1, M by E at position 1, M by K at position 1, M by N at position 1, M by R at position 1, M by S at position 1, L by D at position 5, L by E at position 5, L by K at position 5, L by N at position 5, L by R at position 5, L by S at position 5, L by D at position 6, L by E at position 6, L by K at position 6, L by N at position 6, L by R at position 6, L by S at position 6, L by Q at position 6, L by T at position 6, F by E at position 8, F by K at position 8, F by R at position 8, F by D at position 8, L by D at position 9, L by E at position 9, L by K at position 9, L by N at position 9, L by R at position 9, L by S at position 9, Q by D at position 10, Q by E at position 10, Q by K at position 10, Q by N at position 10, Q by R at position 10, Q by S at position 10, Q by T at position 10, S by D at position 12, S by E at position 12, S by K at position 12, S by R at position 12, S by D at position 13, S by E at position 13, S by K at position 13, S by R at position 13, S by N at position 13, S by Q at position 13, S by T at position 13, N by D at position 14, N by E at position 14, N by K at position 14, N by Q at position 14, N by R at position 14, N by S at position 14, N by T at position 14, F by D at position 15, F by E at position 15, F by K at position 15, F by R at position 15, Q by D at position 16, Q by E at position 16, Q by K at position 16, Q by N at position 16, Q by R at position 16, Q by S at position 16, Q by T at position 16, C by D at position 17, C by E at position 17, C by K at position 17, C by N at position 17, C by Q at position 17, C by R at position 17, C by S at position 17, C by T at position 17, L by N at position 20, L by Q at position 20, L by R at position 20, L by S at position 20, L by T at position 20, L by D at position 20, L by E at position 20, L by K at position 20, W by D at position 22, W by E at position 22, W by K at position 22, W by R at position 22, Q by D at position 23, Q by E at position 23, Q by K at position 23, Q by R at position 23, L by D at position 24, L by E at position 24, L by K at position 24, L by R at position 24, W by D at position 79, W by E at position 79, W by K at position 79, W by R at position 79, N by D at position 80, N by E at position 80, N by K at position 80, N by R at position 80, T by D at position 82, T by E at position 82, T by K at position 82, T by R at position 82, I by D at position 83, I by E at position 83, I by K at position 83, I by R at position 83, I by N at position 83, I by Q at position 83, I by S at position 83, I by T at position 83, N by D at position 86, N by E at position 86, N by K at position 86, N by R at position 86, N by Q at position 86, N by S at position 86, N by T at position 86, L by D at position 87, L by E at position 87, L by K at position 87, L by R at position 87, L by N at position 87, L by Q at position 87, L by S at position 87, L by T at position 87, A by D at position 89, A by E at position 89, A by K at position 89, A by R at position 89, N by D at position 90, N by E at position 90, N by K at position 90, N by Q at position 90, N by R at position 90, N by S at position 90, N by T at position 90, V by D at position 91, V by E at position 91, V by K at position 91, V by N at position 91, V by Q at position 91, V by R at position 91, V by S at position 91, V by T at position 91, Q by D at position 94, Q by E at position 94, Q by Q at position 94, Q by N at position 94, Q by R at position 94, Q by S at position 94, Q by T at position 94, I by D at position 95, I by E at position 95, I by K at position 95, I by N at position 95, I by Q at position 95, I by R at position 95, I by S at position 95, I by T at position 95, H by D at position 97, H by E at position 97, H by K at position 97, H by N at position 97, H by Q at position 97, H by R at position 97, H by S at position 97, H by T at position 97, L by D at position 98, L by E at position 98, L by K at position 98, L by N at position 98, L by Q at position 98, L by R at position 98, L by S at position 98, L by T at position 98, V by D at position 101, V by E at position 101, V by K at position 101, V by N at position 101, V by Q at position 101, V by R at position 101, V by S at position 101, V by T at position 101, M by C at position 1, L by C at position 6, Q by C at position 10, S by C at position 13, Q by C at position 16, L by C at position 17, V by C at position 101, L by C at position 98, H by C at position 97, Q by C at position 94, V by C at position 91, N by C at position 90,wherein residue 1 corresponds to residue 1 of the mature IFNβ
cytokine set forth in SEQ ID NOS;
196.
- cytokine of claim 309, selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
-
329. A modified IFNβ
- cytokine of claim 309 selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
196, or any combination thereof, corresponding to the replacement of;
D by Q at position 39, D by H at position 39, D by G at position 39, E by Q at position 42, E by H at position 42, K by Q at position 45, K by T at position 45, K by S at position 45, K by H at position 45, L by V at position 47, L by I at position 47, L by T at position 47, L by Q at position 47, L by H at position 47, L by A at position 47, K by Q at position 52, K by T at position 52, K by S at position 52, K by H at position 52, F by I at position 67, F by V at position 67, R by H at position 71, R by Q at position 71, D by H at position 73, D by G at position 73, D by Q at position 73, E by Q at position 81, E by H at position 81, E by Q at position 107, E by H at position 107, K by Q at position 108, K by T at position 108, K by S at position 108, K by H at position 108, E by Q at position 109, E by H at position 109, D by Q at position 110, D by H at position 110, D by G at position 110, F by I at position 111, F by V at position 111, R by H at position 113, R by Q at position 113, L by V at position 116, L by I at position 116, L by T at position 116, L by Q at position 116, L by H at position 116, L by A at position 116, L by V at position 120, L by I at position 120, L by T at position 120, L by Q at position 120, L by H at position 120, L by A at position 120, K by Q at position 123, K by T at position 123, K by S at position 123, K by H at position 123, R by H at position 124,, R by Q at position 124, R by H at position 128, R by Q at position 128, L by V at position 130, L by I at position 130, L by T at position 130, L by Q at position 130, L by H at position 130, L by A at position 130, K by Q at position 134, K by T at position 134, K by S at position 134, K by H at position 134, K by Q at position 136, K by T at position 136, K by S at position 136, K by H at position 136, E by Q at position 137, E by H at position 137, Y by H at position 163, Y by I at position 1631, R by H at position 165, R by Q at position 165, wherein the first amino acid listed is substituted by the second at the position indicated.
- cytokine of claim 309 selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
-
330. A modified IFNβ
- cytokine of claim 309 selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
196, or any combination thereof, corresponding to the replacement of;
M by V at position 1, M by I at position 1, M by T at position 1, M by Q at position 1, M by A at position 1, L by V at position 5, L by I at position 5, L by T at position 5, L by Q at position 5, L by H at position 5, L by A at position 5, F by I at position 8, F by V at position 8, L by V at position 9, L by I at position 9, L by T at position 9, L by Q at position 9, L by H at position 9, L by A at position 9, R by H at position 11, R by Q at position 11, F by I at position 15, F by V at position 15, K by Q at position 19, K by T at position 19, K by S at position 19, K by H at position 19, W by S at position 22, W by H at position 22, N by H at position 25, N by S at position 25, N by Q at position 25, R by H position 27, R by Q position 27, L by V at position 28, L by I at position 28, L by T at position 28, L by Q at position 28, L by H at position 28, L by A at position 28, E by Q at position 29, E by H at position 29, Y by H at position 30, Y by I at position 30, L by V at position 32, L by I at position 32, L by T at position 32, L by Q at position 32, L by H at position 32, L by A at position 32, K by Q at position 33, K by T at position 33, K by S at position 33, K by H at position 33, R by H at position 35, R by Q at position 35, M by V at position 36, M by I at position 36, M by T at position 36, M by Q at position 36, M by A at position 36, D by Q at position 39, D by H at position 39, D by G at position 39, E by Q at position 42, E by H at position 42, K by Q at position 45, K by T at position 45, K by S at position 45, K by H at position 45, L by V at position 47, L by I at position 47, L by T at position 47, L by, Q at position 47, L by H at position 47, L by A at position 47, K by Q at position 52, K by T at position 52, K by S at position 52, K by H at position 52, F by I at position 67, F by V at position 67, R by H at position 71, R by Q at position 71, D by Q at position 73, D by H at position 73, D by G at position 73, E by Q at position 81, E by H at position 81, E by Q at position 85, E by H at position 85, Y by H at position 92, Y by I at position 92, K by 0 at position 99, K by T at position 99, K by S at position 99, K by H at position 99, E by Q at position 103, E by H at position 103, E by Q at position 104, E by H at position 104, K by Q at position 105, K by T at position 105, K by S at position 105, K by H at position 105, E by Q at position 107, E by H at position 107, K by Q at position 108, K by T at position 108, K by S at position 108, K by H at position 108, E by Q at position 109, E by H at position 109, D by Q at position 110, D by H at position 110, D by G at position 110, F by I at position 111, F by V at position 111, R by H at position 113, R by Q at position 113, L by V at position 116, L by I at position 116, L by T at position 116, L by Q at position 116, L by H at position 116, L by A at position 116, L by V at position 120, L by I at position 120, L by T at position 120, L by Q at position 120, L by H at position 120, L by A at position 120, K by Q at position 123, K by T at position 123, K by S at position 123, K by H at position 123, R by H at position 124, R by Q at position 124, R by H at position 128, R by Q at position 128, L by V at position 130, L by I at position 130, L by T at position 130, L by Q at position 130, L by H at position 130, L by A at position 130, K by Q at position 134, K by T at position 134, K by S at position 134, K by H at position 134, K by Q at position 136, K by T at position 136, K by S at position 136, K by H at position 136, E by Q at position 137, E by H at position 137, Y by H at position 138, Y by I at position 138, R by H at position 152, R by Q at position 152, Y by H at position 155, Y by I at position 155, R by H at position 159, R by Q at position 159, Y by H at position 163, Y by I at position 163, R by H at position 165, R by Q at position 165, M by D at position 1, M by E at position 1, M by K at position 1, M by N at position 1, M by R at position 1, M by S at position 1, L by D at position 5, L by E at position 5, L by K at position 5, L by N at position 5, L by R at position 5, L by S at position 5, L by D at position 6, L by E at position 6, L by K at position 6, L by N at position 6, L by R at position 6, L by S at position 6, L by Q at position 6, L by T at position 6, F by E at position 8, F by K at position 8, F by R at position 8, F by D at position 8, L by D at position 9, L by E at position 9, L by K at position 9, L by N at position 9, L by R at position 9, L by S at position 9, Q by D at position 10, Q by E at position 10, Q by K at position 10, Q by N at position 10, Q by R at position 10, Q by S at position 10, Q by T at position 10, S by D at position 12, S by E at position 12, S by K at position 12, S by R at position 12, S by D at position 13, S by E at position 13, S by K at position 13, S by R at position 13, S by N at position 13, S by Q at position 13, S by T at position 13, N by D at position 14, N by E at position 14, N by K at position 14, N by Q at position 14, N by R at position 14, N by S at position 14, N by T at position 14, F by D at position 15, F by E at position 15, F by K at position 15, F by R at position 15, Q by D at position 16, Q by E at position 16, Q by K at position 16, Q by N at position 16, Q by R at position 16, Q by S at position 16, Q by T at position 16, C by D at position 17, C by E at position 17, C by K at position 17, C by N at position 17, C by Q at position 17, C by R at position 17, C by S at position 17, C by T at position 17, L by N at position 20, L by Q at position 20, L by R at position 20, L by S at position 20, L by T at position 20, L by D at position 20, L by E at position 20, L by K at position 20, W by D at position 22, W by E at position 22, W by K at position 22, W by R at position 22, Q by D at position 23, Q by E at position 23, Q by K at position 23, Q by R at position 23, L by D at position 24, L by E at position 24, L by K at position 24, L by R at position 24, W by D at position 79, W by E at position 79, W by K at position 79, W by R at position 79, N by D at position 80, N by E at position 80, N by K at position 80, N by R at position 80, T by D at position 82, T by E at position 82, T by K at position 82, T by R at position 82, I by D at position 83, I by E at position 83, I by K at position 83, I by R at position 83, I by N at position 83, I by Q at position 83, I by S at position 83, I by T at position 83, N by D at position 86, N by E at position 86, N by K at position 86, N by R at position 86, N by Q at position 86, N by S at position 86, N by T at position 86, L by D at position 87, L by E at position 87, L by K at position 87, L by R at position 87, L by N at position 87, L by Q at position 87, L by S at position 87, L by T at position 87, A by D at position 89, A by E at position 89, A by K at position 89, A by R at position 89, N by D at position 90, N by E at position 90, N by K at position 90, N by Q at position 90, N by R at position 90, N by S at position 90, N by T at position 90, V by D at position 91, V by E at position 91, V by K at position 91, V by N at position 91, V by Q at position 91, V by R at position 91, V by S at position 91, V by T at position 91, Q by D at position 94, Q by E at position 94, Q by Q at position 94, Q by N at position 94, Q by R at position 94, Q by S at position 94, Q by T at position 94, I by D at position 95, I by E at position 95, I by K at position 95, 1by N at position 95, I by Q at position 95, I by R at position 95, I by S at position 95, I by T at position 95, H by D at position 97, H by E at position 97, H by K at position 97, H by N at position 97, H by Q at position 97, H by R at position 97, H by S at position 97, H by T at position 97, L by D at position 98, L by E at position 98, L by K at position 98, L by N at position 98, L by Q at position 98, L by R at position 98, L by S at position 98, L by T at position 98, V by D at position 101, V by E at position 101, V by K at position 101, V by N at position 101, V by Q at position 101, V by R at position 101, V by S at position 101, V by T at position 101, M by C at position 1, L by C at position 6, Q by C at position 10, S by C at position 13, Q by C at position 16, L by C at position 17, V by C at position 101, L by C at position 98, H by C at position 97, Q by C at position 94, V by C at position 91, N by C at position 90, D by Q at position 39, D by H at position 39, D by G at position 39, E by Q at position 42, E by H at position 42, K by Q at position 45, K by T at position 45, K by S at position 45, K by H at position 45, L by V at position 47, L by I at position 47, L by T at position 47, L by Q at position 47, L by H at position 47, L by A at position 47, K by Q at position 52, K by T at position 52, K by S at position 52, K by H at position 52, F by I at position 67, F by V at position 67, R by H at position 71, R by Q at position 71, D by H at position 73, D by G at position 73, D by Q at position 73, E by Q at position 81, E by H at position 81, E by Q at position 107, E by H at position 107, K by Q at position 108, K by T at position 108, K by S at position 108, K by H at position 108, E by Q at position 109, E by H at position 109, D by Q at position 110, D by H at position 110, D by G at position 110, F by I at position 111, F by V at position 111, R by H at position 113, R by Q at position 113, L by V at position 116, L by I at position 116, L by T at position 116, L by Q at position 116, L by H at position 116, L by A at position 116, L by V at position 120, L by I at position 120, L by T at position 120, L by Q at position 120, L by H at position 120, L by A at position 120, K by Q at position 123, K by T at position 123, K by S at position 123, K by H at position 123, R by H at position 124, R by Q at position 124, R by H at position 128, R by Q at position 128, L by V at position 130, L by I at position 130, L by T at position 130, L by Q at position 130, L by H at position 130, L by A at position 130, K by Q at position 134, K by T at position 134, K by S at position 134, K by H at position 134, K by Q at position 136, K by T at position 136, K by S at position 136,, K by H at position 136, E by Q at position 137, E by H at position 137, Y by H at position 163, Y by I at position 1631, R by H at position 165, R by Q at position 165, wherein the first amino acid listed is substituted by the second at the position indicated.
- cytokine of claim 309 selected from the group consisting of proteins comprising one or more single amino acid replacements in SEQ ID NOS;
-
331. A modified IFNβ
- of claim 330 selected from the group consisting of a modified IFNβ
set forth in any of SEQ ID Nos.234-289, 989-1302.
- of claim 330 selected from the group consisting of a modified IFNβ
-
2. The modified cytokine of claim 1, selected from the group consisting of a member of the interferons/interleukin-10 protein family, a member of the long-chain cytokine family and a member of the short-chain cytokine family, wherein the modified cytokine is a modified interferon α
-
86. A modified IL-10 cytokine, comprising mutations at one or more amino acid residues of IL-10 corresponding to SEQ ID NO:
- 200 at positions 49, 50, 52, 53, 54, 55, 56, 57, 59, 60, 67, 68, 71, 72, 74, 75, 78, 81, 84, 85, 86, and 88, wherein the mutations comprise insertions, deletions and replacements of the native amino acid residue(s).
-
250. A method for generating a protein or peptide molecule, having a predetermined property or activity, the method comprising:
-
(a) identifying, within a target protein or peptide or plurality thereof, one or more target amino acids, wherein;
each target amino acid is designated an in silico-HIT (is-HIT); and
the is-HIT target amino acids are determined by identifying structurally homologous loci between the evolving target protein and a reference protein possessing the desired activity;
(b) identifying one or more replacement amino acids, specific for each is-HIT, wherein each single amino acid replacement within the target protein or peptide is designated as a candidate LEAD protein;
(c) producing a population of sets of nucleic acid molecules that encode each of the candidate LEAD proteins, wherein each candidate LEAD protein contains a single amino acid replacement, and wherein each polynucleotide in a set encodes a candidate LEAD protein that differs by one amino acid from the target protein or peptide;
(d) introducing each set of nucleic acid molecules into host cells and expressing the encoded candidate LEAD proteins, wherein the host cells are present in an addressable array;
(e) individually screening the sets of encoded candidate LEAD proteins to identify one or more proteins that has an activity that differs from an activity an unmodified target protein, wherein each such protein is designated a LEAD mutant protein;
- View Dependent Claims (251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278)
-
251. The method of claim 250, wherein the predetermined property or activity of the evolved modified protein is increased resistance to proteolysis.
-
252. The method of claim 250, wherein the target proteins comprise a family.
-
253. The method of claim 250, wherein target proteins are cytokines.
-
254. The method of claim 253, wherein the cytokines are selected from the group consisting of interleukin-10 (IL-10), interferon beta (IFNβ
- ), interferon alpha (IFNα
), interferon gamma (IFN-y), granulocyte colony stimulating factor (G-CSF), leukemia inhibitory factor (LIF), human growth hormone (hGH), ciliary neurotrophic factor (CNTF), leptin, oncostatin M, interleukin-6 (IL-6) and interleukin-12 (IL-12), erythropoietin (EPO), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), Flt3 ligand and stem cell factor (SCF).
- ), interferon alpha (IFNα
-
255. The method of claim 250, wherein each candidate lead is individually prepared and screened to identify leads.
-
256. The method of claim 250, wherein the nucleic acid molecules comprise plasmids;
- and the cells are eukaryotic cells that are transfected with the plasmids, or the nucleic acid molecules comprise plasmids and the cells are bacterial cells.
-
257. The method of claim 250, wherein the nucleic acid molecules in step (c) are produced by site-specific mutagenesis.
-
258. The method of claim 250, further comprising:
-
(e) generating a population of sets of nucleic acid molecules encoding a set of candidate super-LEAD proteins, wherein each candidate super-LEAD protein comprises a combination of two or more of the single amino acid mutations derived from two or more LEAD mutant proteins;
(f) introducing each set of nucleic acid molecules encoding candidate super-LEADs into cells and expressing the encoded candidate super-LEAD proteins; and
(g) individually screening the sets of encoded candidate super-LEAD proteins to identify one or more proteins that has activity that differs from the unmodified target protein and has properties that differ from the original LEADs, wherein each such protein is designated a super-LEAD.
-
-
259. The method of claim 258, wherein the nucleic acid molecules in step (f) are generated by a method selected from among additive directional mutagenesis (ADM), multi-overlapped primer extensions, oligonucleotide-mediated mutagenesis, nucleic acid shuffling, recombination, site-specific mutagenesis, and de novo synthesis.
-
260. The method of claim 250, wherein candidate leads are produced by replacing to a restricted subset of amino acids along the full length of a target protein.
-
261. The method of claim 250, wherein the replacement amino acids identified in step (b) correspond to a restricted subset of the 19 remaining non-native amino acids.
-
262. The method of claim 250, wherein the nucleic acids of step (c) are produced by systematically replacing each codon that is an is-HIT, with one or more codons encoding a restricted subset of the remaining amino acids, to produce nucleic acid molecules each differing by at least one codon and encoding candidate LEADs.
-
263. The method of claim 258, wherein the number of LEAD amino acid positions generated on a single nucleic acid molecule is selected from the group consisting of:
- two, three, four, five, six, seven, eight, nine, ten or more LEAD amino acid positions up to all of the LEAD amino acid positions.
-
264. The method of claim 250, wherein the LEADs or super-LEADs possess increased resistance to proteolysis compared to unmodified target protein.
-
265. The method of claim 250, wherein the change in activity is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to the activity of the unmodified target protein.
-
266. The method of claim 250, wherein the change in activity is not more than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to he activity of the unmodified target protein.
-
267. The method of claim 250, wherein the change in activity is at least about 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times, 200 times, 300 times, 400 times, 500 times, 600 times, 700 times, 800 times, 900 times, 1000 times, or more greater than the activity of the unmodified target protein.
-
268. The method of claim 250, wherein the replacing amino acids are selected using Percent Accepted Mutations (PAM) matrices.
-
269. The method of claim 250, wherein the replacing amino acids are pseudo-wild type amino acids.
-
270. The method of claim 250, wherein identification of the structurally homologous loci between the evolving target protein and a reference protein possessing the desired activity, comprises:
-
(a) comparing the 3-dimensional structures of the two or more proteins to identify regions of high coincidence between their backbones, said regions designated as structurally homologous regions; and
(b) identifying is-HIT structurally homologous loci on the evolving protein that correspond to structurally related is-HIT amino acid positions within a structurally homologous region of the reference protein.
-
-
271. The method of claim 270, wherein the comparison of the 3-dimensional structures of the evolving target protein and the reference protein is based upon their 3-dimensinal strucutures not upon alignment between their respective primary sequences.
-
272. The method of claim 270, wherein the evolving target protein and the reference protein belong to a family of sequence-related proteins.
-
273. The method of claim 270, wherein the evolving target protein and the reference protein belong respectively are non-related proteins or sequence-non-related proteins.
-
274. The method of claim 270, wherein the degree of coincidence between the 3-dimensional structures of the evolving target protein and the reference protein is in a region selected from the group consisting of:
-
(a) a small region on the two proteins;
(b) a large region on the two proteins; and
(c) a region that covers the full length of one or both of the proteins.
-
-
275. The method of claim 270, wherein the degree of coincidence between the 3-dimensional structures of the evolving target protein and of the reference protein is determined by superposition and RMS deviation calculations using any combination of one or more of the peptide backbone atoms selected from the group consisting of:
- N, C, C(C═
O), O and CA.
- N, C, C(C═
-
276. The method of claim 275, wherein the superposition and RMS deviation calculations are made using all of the peptide backbone atoms selected from the group consisting of:
- N, C, C(C═
O), O and CA, when present.
- N, C, C(C═
-
277. The method of claim 275, wherein the superposition and RMS deviation calculations are carried out on a subset of regions or domains of a larger protein that adopts a structure similar to a smaller protein.
-
278. The method of claim 275, wherein the degree of coincidence between the 3-dimensional structures of the evolving target protein and the reference protein is obtained using any combination of one or more of either Class Architecture, Topology and Homologous Superfamily (CATH);
- Combinatorial Extension of the optimal path (CE);
Fold Classification based of Structure-Structure Alignment of Proteins (FSSP);
Structural Classification of Proteins (SCOP);
Vector Alignment Search Tool (VAST), and TOP.
- Combinatorial Extension of the optimal path (CE);
-
251. The method of claim 250, wherein the predetermined property or activity of the evolved modified protein is increased resistance to proteolysis.
-
-
281. A method of generating a modified protein or cytokine having a pre-selected altered phenotype, comprising:
-
modifying a first protein or cytokine by a directed evolution method to produce an evolved protein or cytokine that has the altered phenotype to identify altered loci; and
comparing the structures of one or more members of the protein or cytokine family to identify structurally homologous loci for alteration;
altering the identified loci in members of the protein or cytokine family to produce proteins or cytokines that have the altered phenotype. - View Dependent Claims (282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305)
-
282. The method of claim 281, wherein directed evolution is effected by a rational directed evolution method.
-
283. The method of claim 281, wherein directed evolution is effected by a 2-dimensional rational scanning.
-
284. The method of claim 281, wherein identification of the structurally homologous loci between the evolved protein or cytokine and members of the protein or cytokine family, further comprises:
-
(a) comparing the 3-dimensional structures of the evolved protein or cytokine with one or more members of the protein or cytokine family to identify regions of high coincidence between their backbones, said regions designated as structurally homologous regions; and
(b) identifying is-HIT structurally homologous loci on the members of the protein or cytokine family that correspond to structurally related is-HIT amino acid positions within a structurally homologous region of the evolved protein or cytokine.
-
-
285. The method of claim 284, wherein the comparison of the 3-dimensional structures of the members of the protein or cytokine family and the evolved protein or cytokine is made irrespective of any alignment between their respective sequences.
-
286. The method of claim 284, wherein the degree of coincidence between the 3-dimensional structures of the members of the protein or cytokine family and the evolved protein or cytokine is in a region selected from the group consisting of:
-
(a) a small region on the two proteins;
(b) a large region on the two proteins; and
(c) a region that covers the full length of one or both of the proteins.
-
-
287. The method of claim 284, wherein the degree of coincidence between the 3-dimensional structures of the members of the protein or cytokine family and of the evolved protein or cytokine is determined by superposition and RMS deviation calculations using any combination of one or more of the peptide backbone atoms selected from the group consisting of:
- N, C, C(C═
O), O and CA.
- N, C, C(C═
-
288. The method of claim 287, wherein the superposition and RMS deviation calculations are made using all of the peptide backbone atoms present selected from group the consisting of:
- N, C, C(C═
O), O and CA.
- N, C, C(C═
-
289. The method of claim 287, wherein the superposition and RMS deviation calculations are carried out on a subset of regions or domains of a larger protein that adopts a structure similar to a smaller protein.
-
290. The method of claim 284, wherein the degree of coincidence between the 3-dimensional structures of the members of the protein or cytokine family and the evolved protein or cytokine is obtained using any combination of one or more of either CATH (Class Architecture, Topology and Homologous Superfamily);
- CE (Combinatorial Extension of the optimal path);
FSSP (Fold Classification based of Structure-Structure Alignment of Proteins);
SCOP (Structural Classification of Proteins);
VAST (Vector Alignment Search Tool), and TOP.
- CE (Combinatorial Extension of the optimal path);
-
291. The method of claim 283, wherein the 2-dimensional rational scanning method comprises:
-
(a) identifying, within the first protein or cytokine, one or more target amino acids amenable to providing the altered phenotype upon amino acid replacement, wherein each target amino acid is designated an in silico-HIT (is-HIT);
(b) identifying one or more replacement amino acids, specific for each is-HIT, amenable to providing the altered phenotype upon amino acid replacement, wherein each single amino acid replacement within the protein or cytokine is designated as a candidate LEAD protein;
(c) producing a population of sets of nucleic acid molecules that encode each of the candidate LEAD proteins, wherein each candidate LEAD protein comprises a single amino acid replacement, and wherein each polynucleotide in a set encodes a candidate LEAD protein that differs by one amino acid from the unmodified protein or cytokine;
(d) introducing each set of nucleic acid molecules into host cells and expressing the encoded candidate LEAD proteins, wherein the host cells are present in an addressable array;
(e) individually screening the sets of encoded candidate LEAD proteins to identify one or more candidate LEAD proteins that has activity that differs from the unmodified protein or cytokine, wherein each such protein is designated a LEAD mutant protein.
-
-
292. The method of claim 291, wherein the array comprises a solid support with wells;
- and each well contains one set of cells.
-
293. The method of claim 291, wherein the nucleic acid molecules comprise plasmids;
- and the cells are eukaryotic cells that are transfected with the plasmids.
-
294. The method of claim 291, wherein the nucleic acid molecules comprise plasmids and the cells are bacterial cells.
-
295. The method of claim 291, wherein the nucleic acid molecules in step (c) are produced by site-specific mutagenesis.
-
296. The method of claim 291, further comprising:
-
(f) generating a population of sets of nucleic acid molecules encoding a set of candidate super-LEAD proteins, wherein each candidate super-LEAD protein comprises a combination of two or more of the single amino acid mutations derived from two or more LEAD mutant proteins;
(g) introducing each set of nucleic acid molecules encoding candidate super-LEADs into cells and expressing the encoded candidate super-LEAD proteins; and
(h) individually screening the sets of encoded candidate super-LEAD proteins to identify one or more proteins that has activity that differs from the unmodified protein or cytokine and has properties that differ from the original LEADs, wherein each such protein is designated a super-LEAD.
-
-
297. The method of claim 296, wherein the nucleic acid molecules in step (f) are produced by a method selected from among Additive Directional Mutagenesis (ADM), multi-overlapped primer extensions, oligonucleotide-mediated mutagenesis, nucleic acid shuffling, recombination, site-specific mutagenesis, and de novo synthesis.
-
298. The method of claim 291, wherein the is-HITs identified in step (a) correspond to a restricted subset of amino acids along the full length target protein.
-
299. The method of claim 291, wherein the replacement amino acids identified in step (b) correspond to a restricted subset of the 19 remaining non-native amino acids.
-
300. The method of claim 291, wherein the nucleic acids of step (c) are produced by systematically replacing each codon that is an is-HIT, with one or more codons encoding a restricted subset of the remaining amino acids, to produce nucleic acid molecules each differing by at least one codon and encoding candidate LEADs.
-
301. The method of claim 296, wherein the number of LEAD amino acid positions generated on a single nucleic acid molecule is selected from the group consisting of:
- two, three, four, five, six, seven, eight, nine, ten or more LEAD amino acid positions up to all of the LEAD amino acid positions.
-
302. The method of claim 291, wherein the LEADs or super-LEADs possess increased resistance to proteolysis compared to unmodified protein or cytokine.
-
303. The method of claim 291, wherein the change in activity is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the activity of the unmodified target protein.
-
304. The method of claim 291, wherein the change in activity is not more than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%, of the activity of the unmodified target protein.
-
305. The method of claim 291, wherein the change in activity is at least about 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times, 200 times, 300 times, 400 times, 500 times, 600 times, 700 times, 800 times, 900 times, 1000 times, or more greater or less than the activity of the unmodified target protein.
-
282. The method of claim 281, wherein directed evolution is effected by a rational directed evolution method.
-
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeHanAll Biopharma Co. Ltd.
-
Original AssigneeHanAll Biopharma Co. Ltd.
-
InventorsGuyon, Thierry, Drittanti, Lila, Vega, Manuel, Gantier, Rene
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current530/351
-
CPC Class CodesA61K 38/00 Medicinal preparations cont...A61P 1/16 for liver or gallbladder di...A61P 11/00 Drugs for disorders of the ...A61P 19/02 for joint disorders, e.g. a...A61P 25/16 Anti-Parkinson drugsA61P 25/28 for treating neurodegenerat...A61P 3/00 Drugs for disorders of the ...A61P 3/10 for hyperglycaemia, e.g. an...A61P 31/00 Antiinfectives, i.e. antibi...A61P 35/00 Antineoplastic agentsA61P 37/00 Drugs for immunological or ...A61P 37/08 Antiallergic agents antiast...A61P 7/00 Drugs for disorders of the ...A61P 9/00 Drugs for disorders of the ...C07K 14/475 Growth factors; Growth regu...C07K 14/505 Erythropoietin [EPO]C07K 14/52 Cytokines; Lymphokines; Int...C07K 14/53 Colony-stimulating factor [...C07K 14/535 Granulocyte CSF; Granulocyt...C07K 14/54 Interleukins [IL]C07K 14/555 : Interferons [IFN]C07K 14/575 : Hormones derived from pro-o...C07K 14/61 : Growth hormone [GH], i.e. s...